65O CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N ± ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC

作者：Solange Peters, Daniel S.W. Tan, David E. Gerber, James J. Urbanic, S.S. Ramalingam, Jin Yu, Ligang Xing, Achim Rittmeyer, T-E. Ciuleanu, J. Menezes, H.R. Kim, C.I. Rojas, Konstantinos Syrigos, Hirokatsu Hayashi, Anoop Haridass, Stéphanie Bordenave-Juchereau, Raheel Nathani, Geetha Pudussery, Ling Yang, Dirk De Ruysscher · 发表于：Immuno-Oncology Technology · 年份：2024 · DOI：10.1016/j.iotech.2024.100808 · 被引用次数：22 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Radiopharmaceutical Chemistry and Applications

CCRT followed by D consolidation is the standard of care (SOC) for patients (pts) with unresectable stg III NSCLC; however, more than half of pts still have disease progression and die within 5 years. Dual IO with PD-(L)1 and CTLA-4 inhibitors has shown durable benefit in pts with metastatic NSCLC and may improve antitumor control as consolidation after CCRT in pts with unresectable stg III NSCLC. Here, we report final results from CheckMate 73L, a phase 3 study comparing N + CCRT followed by consolidation N + I or N v CCRT followed by D in this pt population.